Skip to content

An Extension of the Written Disclosure Paradigm to the Psychotherapeutic Context: Can Systematic Changes in Emotion Regulation Strategy Reduce Distress and Improve Immune Function in Cancer Patients Living in Remission.

Evaluation of the Efficacy of Emotion Focused Psychotherapies for Reducing Distress and Improving Immune Function and Quality of Life in Cancer Patients Living in Remission.

Status
Not yet recruiting
Phases
Phase 1
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12605000783628
Acronym
EEFP1
Enrollment
70
Registered
2005-12-08
Start date
2006-01-23
Completion date
Unknown
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Full ethical approval to proceed with the project has been given by all Institutions described above.

Interventions

In the first of three studies that aim to the efficacy of psychotherapies focused on the expression of emotion, Pennebaker & Beal's (1986) written disclosure methodology will be applied to an individual psychotherapeutic context. In an extension of the Pennebaker & Beal (1986) paradigm; and in accord with recent theoretical developments (i.e., A to D Emotion Theory; Pennebaker & Chung (In-Press)), Participants allocated to the Treatment group will be encouraged to use emotion labels when expres

In the first of three studies that aim to the efficacy of psychotherapies focused on the expression of emotion, Pennebaker & Beal's (1986) written disclosure methodology will be applied to an individual psychotherapeutic context. In an extension of the Pennebaker & Beal (1986) paradigm; and in accord with recent theoretical developments (i.e., A to D Emotion Theory; Pennebaker & Chung (In-Press)), Participants allocated to the Treatment group will be encouraged to use emotion labels when expressing their deepest thoughts and feelings with respect to the following topics: Diagnosis (weeks 1 & 6); Treatment/Waiting for Results (weeks 2 & 7); Living in Remission (weeks 3 & 8); Most Distressing/Traumatic Experience (weeks 4 & 5). Participants randomly allocated to the Treatment group will attend 8 x 1 hour, individual sessions.

Sponsors

The Cancer Centre, The Royal Adelaide Hospital
Lead SponsorHospital

Study design

Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Blinded (masking used)

Eligibility

Sex/Gender
All
Age
18 Years to 74 Years
Healthy volunteers
No

Inclusion criteria

Received a diagnosis of Stage I, or II cancer (solid neoplasm) within the past 12 months. Score more than 4 using the General Health Questionnaire (GHQ-12).A minimum of two months must have elapsed since surgery, chemotherapy or radiation therapy. Be able to speak fluent English, have no apparent intellectual impairment.Reside within the Adelaide metropolitan area and be able to attend psychotherapy sessions on a weekly basis (for 1 hour) over an 8 week period.

Exclusion criteria

A diagnosis of Heart Disease, Diabetes, Rheumatoid Arthritis, Addisons disease, Cushings Disease or Lupus.Are taking medication that suppresses the immune system, are pregnant or breast feeding.Have an infectious disease such as HIV, HBV, HCV.DSM-IV diagnosis of psychotic disorder.GHQ score less than 4.Are physically unwell at the time of testing, and/or are physically unable to attend trial. Participated in a previous emotion focused psychotherapy trial.

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026